iMedicor announced its launch of Access Pharmaceuticals' MuGard product through its pharma online marketing portal, ClearLobby, and its direct sales channel, Direct Medical Solutions.
According to officials, the initial phase of the marketing program includes a targeted MuGard sampling program to select iMedicor users and the DMS' physician network. As previously announced, iMedicor has been selected by Access Pharmaceuticals, to support the North American commercial launch efforts of its lead product, MuGard - an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis and stomatitis, a side effect of radiotherapy and/or chemotherapy.
MuGard is now being introduced to Centers of Excellence, Key Opinion Leaders, cancer research centers and selected physicians in the United States. The initial release of MuGard samples is part of a joint project that includes participation from iMedicor's user base and DMS, a network of direct field representatives with relationships to physicians and their practices. The full national launch is expected during the third quarter using iMedicor's Physician Communication System (PCS), and iMedicor's strategic partnership with Direct Medical Solutions (DMS) and other strategic partners.
"After many months of planning, we look forward to assisting Access Pharma with its introduction of MuGard on a national level," said Fred Zolla, CEO of iMedicor. He continued, "MuGard represents a potential blockbuster product that could significantly improve the quality of life for patients undergoing certain cancer treatments. iMedicor's ability to deliver essential information from a trusted source to specific physician audiences will significantly increase Access Pharma's marketing ROI."
"Our collective efforts have led to the positive acceptance of the first phase sampling program throughout the DMS network," commented Marian Bartosiewicz, CEO of DMS. She continued, "We are pleased to be part of the introduction of a product like MuGard that can offer measurable relief to patients undergoing radiation and chemotherapy."
"Teaming up with iMedicor and DMS is an important strategic step in launching MuGard in North America as it provides us the ability to introduce MuGard more rapidly and cost-effectively than we would expect through traditionaldistribution channels to doctors," said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc. He continued, "Along with this initial and on-going sample program, Access will be able to utilize the medical education aspects of the iMedicor system to further inform doctors about oral mucositis and MuGard, and to accelerate commercial uptake in the U.S. market."
Disclosure: No Postitions